{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T21:31:40Z","timestamp":1765229500329,"version":"3.46.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Fluorine\u201018 fluorodeoxyglucose ([18F]FDG) positron emission tomography\/computed tomography (PET\/CT) is an essential examination to stage patients with esophageal cancer; however, the role of posttreatment [18F]FDG PET\/CT in patients with esophageal cancer has not been well explored. We aimed to investigate the prognostic and diagnostic value of posttreatment PET\/CT in patients with esophageal cancer after their definitive treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study enrolled 208 patients with biopsy-proven esophageal cancer. Posttreatment PET\/CT scans were performed greater than or equal to 3 months after the completion of definitive therapy, with a total of 539 scans included in this study. The outcome measures were the diagnostic capacity of PET\/CT and patient survival. Survival analysis was conducted using Kaplan\u2013Meier plots, accompanied by the Mantel\u2013Cox log-rank test and Cox regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The sensitivity, specificity, and accuracy of posttreatment PET\/CT for recurrent tumors were 93.67, 92.65, and 92.95%, respectively. PET\/CT identified recurrent tumors in 24.58% of scans obtained for tumor surveillance and ruled out recurrence in 40.30% of scans obtained with prior clinical suspicion. Negative PET\/CT had a predictive value of 80% for nonrecurrence before the next planned scan, while positive PET results were significantly associated with poorer patient survival following the scan (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001). In the multivariate Cox regression model, the PET\/CT result was identified as an independent prognostic factor [\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001, hazard ratio (HR)=3.818] with a higher hazard ratio compared with the tumor stage (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.01, HR=1.633) or treatment modality (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0002, HR = 2.035).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We illustrate the favorable performance of posttreatment [18F]FDG PET\/CT in both detecting tumor recurrence and evaluating the prognosis of patients with M0 esophageal cancer. These findings imply the potential of [18F]FDG PET\/CT as a follow-up imaging modality in these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mnm.0000000000002004","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T05:00:10Z","timestamp":1751259610000},"page":"816-823","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Investigation of the diagnostic and prognostic impact of posttreatment fluorine-18 fluorodeoxyglucose PET\/computed tomography on M0 esophageal cancer"],"prefix":"10.1097","volume":"46","author":[{"given":"Chang-Shen","family":"Tseng","sequence":"first","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bee-Song","family":"Chang","sequence":"additional","affiliation":[{"name":"Cardiothoracic Surgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Hang","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, Linkou Chang Gung Memorial Hospital, Chang Gung University, Taoyuan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Hsin","family":"Liu","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason Chia-Hsun","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, New Taipei Municipal Tucheng Hospital, New Taipei City"},{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan"},{"name":"College of Medicine, Chang Gung University, Taoyuan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Chieh","family":"Chan","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"},{"name":"School of Medicine, Tzu Chi University, Hualien, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"R1-20251208","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20251208","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0140-6736(12)60643-6","article-title":"Oesophageal carcinoma.","volume":"381","author":"Pennathur","year":"2013","journal-title":"Lancet"},{"key":"R3-20251208","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","article-title":"The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020.","volume":"163","author":"Morgan","year":"2022","journal-title":"Gastroenterology"},{"key":"R4-20251208","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/jamaoncol.2015.0735","article-title":"The global burden of cancer 2013.","volume":"1","author":"Fitzmaurice","year":"2015","journal-title":"JAMA Oncol"},{"key":"R5-20251208","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"key":"R6-20251208","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/SLA.0000000000005638","article-title":"Recurrent disease after esophageal cancer surgery: a substudy of the Dutch nationwide ivory study.","volume":"276","author":"Kalff","year":"2022","journal-title":"Ann Surg"},{"key":"R7-20251208","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1097\/01.JTO.0000437420.38972.fb","article-title":"Esophageal cancer recurrence patterns and implications for surveillance.","volume":"8","author":"Lou","year":"2013","journal-title":"J Thorac Oncol"},{"key":"R8-20251208","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1186\/s12885-023-11568-w","article-title":"Survival outcomes of esophageal cancer patients with recurrence after curative treatments.","volume":"23","author":"Sugawara","year":"2023","journal-title":"BMC Cancer"},{"key":"R9-20251208","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.canrad.2022.09.001","article-title":"Pattern of relapse following three-field lymphadenectomy of esophageal carcinoma and related factors predictive of recurrence.","volume":"27","author":"Xu","year":"2023","journal-title":"Cancer Radiother"},{"key":"R10-20251208","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/jso.26349","article-title":"Nomograms for predicting overall and recurrence-free survival after trimodality therapy for esophageal adenocarcinoma.","volume":"123","author":"Merritt","year":"2021","journal-title":"J Surg Oncol"},{"key":"R11-20251208","doi-asserted-by":"crossref","first-page":"855","DOI":"10.6004\/jnccn.2019.0033","article-title":"Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology.","volume":"17","author":"Ajani","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"R12-20251208","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0016-5107(98)70157-9","article-title":"Endoscopic ultrasound in restaging of esophageal cancer after neoadjuvant chemoradiation.","volume":"48","author":"Isenberg","year":"1998","journal-title":"Gastrointest Endosc"},{"key":"R13-20251208","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/dote.12315","article-title":"Performance of different imaging modalities in assessment of response to neoadjuvant therapy in primary esophageal cancer.","volume":"29","author":"Yip","year":"2016","journal-title":"Dis Esophagus"},{"key":"R14-20251208","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.2004.01.083","article-title":"Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer.","volume":"22","author":"van Westreenen","year":"2004","journal-title":"J Clin Oncol"},{"key":"R15-20251208","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cpet.2017.05.001","article-title":"PET\/computed tomography scanning and precision medicine: esophageal cancer.","volume":"12","author":"Goel","year":"2017","journal-title":"PET Clin"},{"key":"R16-20251208","doi-asserted-by":"crossref","first-page":"864","DOI":"10.2967\/jnumed.111.101568","article-title":"18F-FDG PET\/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data.","volume":"53","author":"Barber","year":"2012","journal-title":"J Nucl Med"},{"key":"R17-20251208","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2967\/jnumed.115.155580","article-title":"Diagnostic performance of (1)(8)F-FDG PET and PET\/CT for the detection of recurrent esophageal cancer after treatment with curative intent: a systematic review and meta-analysis.","volume":"56","author":"Goense","year":"2015","journal-title":"J Nucl Med"},{"key":"R18-20251208","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1148\/radiol.2363041042","article-title":"Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy \u2013 systematic review.","volume":"236","author":"Westerterp","year":"2005","journal-title":"Radiology"},{"key":"R19-20251208","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/00365520802273066","article-title":"Controversies in the use of endoscopic ultrasound in esophageal cancer staging.","volume":"44","author":"Kalaitzakis","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"R20-20251208","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.2967\/jnumed.114.138974","article-title":"Clinical implication of PET\/MR imaging in preoperative esophageal cancer staging: comparison with PET\/CT, endoscopic ultrasonography, and CT.","volume":"55","author":"Lee","year":"2014","journal-title":"J Nucl Med"},{"key":"R21-20251208","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1007\/s00259-019-04387-4","article-title":"Diagnostic value of surveillance (18)F-fluorodeoxyglucose PET\/CT for detecting recurrent esophageal carcinoma after curative treatment.","volume":"46","author":"Kim","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R22-20251208","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1007\/s00259-013-2664-8","article-title":"Diagnostic accuracy of (1)(8)F-FDG PET\/CT for detection of suspected recurrence in patients with oesophageal carcinoma.","volume":"41","author":"Sharma","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R23-20251208","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/RLU.0000000000002291","article-title":"Prognostic value of volumetric parameters of pretreatment 18F-FDG PET\/CT in esophageal cancer: a systematic review and meta-analysis.","volume":"43","author":"Han","year":"2018","journal-title":"Clin Nucl Med"},{"key":"R24-20251208","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3390\/cancers12030607","article-title":"Prognostic value of lymph node-to-primary tumor standardized uptake value ratio in esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.","volume":"12","author":"Lin","year":"2020","journal-title":"Cancers (Basel)"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000002004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T20:00:13Z","timestamp":1765224013000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000002004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000002004","relation":{},"ISSN":["0143-3636","1473-5628"],"issn-type":[{"type":"print","value":"0143-3636"},{"type":"electronic","value":"1473-5628"}],"subject":[],"published":{"date-parts":[[2025,6,30]]}}}